AU2 85
Alternative Names: AU2-85; Oral CDK8 inhibitorLatest Information Update: 05 Aug 2021
At a glance
- Originator Aucentra Therapeutics
- Class Amines; Antineoplastics; Imidazoles; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action Cyclin-dependent kinase 8 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer; Haematological malignancies
Most Recent Events
- 26 Jul 2021 AU2 85 is available for licensing as of 26 Jul 2021. https://www.aucentra.com/partners-investors/
- 26 Jul 2021 Preclinical trials in Cancer in Australia (PO) before April 2021 (Aucentra pipeline, April 2021)
- 26 Apr 2021 Preclinical trials in Haematological malignancies in USA (PO) before April 2021 (Aucentra pipeline, April 2021)